AstraZeneca's Shot Designer Seeks $613 Million Value in IPO.

ASTRAZENECA PLC; VACCINE manufacturing; GOING public (Securities); LISTING of securities; COVID-19 vaccines; HEPATITIS B vaccines

QS69I9T0AFBE (Bloomberg) -- The University of Oxford spinoff that designed AstraZeneca Plc's Covid-19 vaccine is seeking a valuation as high as $613 million in its initial public offering in the U.S., a move to help fund trials for new directions in cancer and other diseases. Keywords: 571951Z@LN; AUTL; AZN@LN; BNTX; GILD; ORTX; VACC; BUSINESS; COS; DRG; HEA; INDUSTRIES; MARKETS; STK EN 571951Z@LN AUTL AZN@LN BNTX GILD ORTX VACC BUSINESS COS DRG HEA INDUSTRIES MARKETS STK The University of Oxford spinoff that designed AstraZeneca Plc's Covid-19 vaccine is seeking a valuation as high as $613 million in its initial public offering in the U.S., a move to help fund trials for new directions in cancer and other diseases. [Extracted from the article]

Copyright of Bloomberg.com is the property of Bloomberg, L.P. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)